Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more
Roivant Sciences Ltd (ROIV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.040x
Based on the latest financial reports, Roivant Sciences Ltd (ROIV) has a cash flow conversion efficiency ratio of -0.040x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-196.48 Million) by net assets ($4.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Roivant Sciences Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Roivant Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Roivant Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roivant Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XPENG INC. SP.ADS/2 CL.A
F:8XPA
|
N/A |
|
MACOM Technology Solutions Holdings Inc
NASDAQ:MTSI
|
0.032x |
|
ROYALTY PHARMA OA DL-0001
F:RPD
|
N/A |
|
Northern Star Resources Ltd
PINK:NESRF
|
0.114x |
|
Shriram Finance Limited
NSE:SHRIRAMFIN
|
-0.069x |
|
Power Grid Corporation of India Limited
NSE:POWERGRID
|
0.150x |
|
Standard Bank Group Limited
PINK:SBGOF
|
0.252x |
|
Metro Inc
PINK:MTRAF
|
0.010x |
Annual Cash Flow Conversion Efficiency for Roivant Sciences Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Roivant Sciences Ltd from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.19 Billion | $-839.45 Million | -0.162x | -36.37% |
| 2024-03-31 | $6.45 Billion | $-765.27 Million | -0.119x | +77.38% |
| 2023-03-31 | $1.61 Billion | $-843.39 Million | -0.525x | -59.58% |
| 2022-03-31 | $2.06 Billion | $-677.73 Million | -0.329x | -28.73% |
| 2021-03-31 | $2.16 Billion | $-552.14 Million | -0.255x | +29.31% |
| 2020-03-31 | $2.11 Billion | $-761.83 Million | -0.361x | +66.94% |
| 2019-03-31 | $937.30 Million | $-1.02 Billion | -1.093x | -- |